Joachim Yahalom

Joachim Yahalom's AcademicInfluence.com Rankings

Joachim Yahalom

Medical

#2850

Historical Rank

Oncology

#151

Historical Rank

medical Degrees

Joachim Yahalom

Philosophy

#10200

Historical Rank

Logic

#5382

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Joachim Yahalom's Degrees

Doctorate Medicine Harvard University
PhD Radiation Oncology Stanford University

Why Is Joachim Yahalom Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joachim Yahalom's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (2008) (2360)
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. (2001) (1010)
Treatment for primary CNS lymphoma: the next step. (2000) (558)
Long-term survival in primary CNS lymphoma. (1998) (542)
Combined modality therapy for primary CNS lymphoma. (1992) (518)
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). (2014) (450)
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. (2006) (449)
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. (2001) (399)
How I treat extramedullary acute myeloid leukemia. (2011) (394)
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. (2004) (372)
Superior Vena Cava Syndrome with Malignant Causes (2007) (367)
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. (2010) (355)
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. (2007) (340)
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. (2013) (337)
Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. (1998) (292)
Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. (2004) (291)
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. (1999) (290)
Intensity-modulated tangential beam irradiation of the intact breast. (1999) (284)
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. (2015) (272)
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. (2006) (261)
NCCN clinical practice guidelines in oncology: multiple myeloma. (2009) (260)
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. (2012) (251)
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. (2003) (249)
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (243)
Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. (1991) (242)
Delayed neurotoxicity in primary central nervous system lymphoma. (2005) (233)
Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. (2014) (230)
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. (2010) (224)
Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. (2005) (217)
Primary breast irradiation in large-breasted or heavy women: analysis of cosmetic outcome. (1991) (213)
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. (1998) (212)
Primary CNS lymphoma (1990) (212)
Primary bone lymphoma: Treatment results and prognostic factors with long‐term follow‐up of 82 patients (2006) (208)
Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. (1985) (207)
Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. (1992) (206)
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. (2015) (206)
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. (2006) (184)
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. (2003) (179)
Clinical practice. Superior vena cava syndrome with malignant causes. (2007) (178)
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma (2007) (170)
Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. (1990) (162)
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease (2004) (153)
The involved field is back: issues in delineating the radiation field in Hodgkin's disease. (2002) (151)
Second malignant neoplasms and cardiovascular disease following radiotherapy. (2012) (139)
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. (2005) (138)
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma (2009) (134)
Non‐hodgkin's lymphomas (2010) (133)
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. (2018) (132)
Non-Hodgkin's lymphomas, version 4.2014. (2014) (131)
NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. (2016) (127)
Radiotherapy in the management of plasma cell tumors. (2000) (125)
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. (2000) (124)
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (122)
Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. (1996) (122)
Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. (1991) (121)
Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). (2018) (121)
Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. (1993) (121)
Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma (2006) (121)
Primary mediastinal large B‐cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999 (2005) (121)
[Treatment of metastatic breast cancer]. (1986) (117)
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. (1994) (115)
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. (2018) (115)
Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. (1994) (115)
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma (2003) (112)
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. (2007) (110)
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. (2003) (110)
Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. (1992) (109)
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy (2009) (105)
Combined‐modality therapy in the treatment of primary central nervous system lymphoma in AIDS (1994) (104)
Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. (1992) (103)
Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. (2008) (103)
Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. (2018) (102)
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. (2017) (101)
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. (2012) (100)
Second Malignant Neoplasms and Cardiovascular Disease Following Radiotherapy (2014) (96)
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low‐grade and intermediate‐grade non‐Hodgkin lymphoma. Results of a prospective randomized study (1993) (94)
Intensity-modulated radiotherapy for lymphoma involving the mediastinum. (2005) (92)
Radiation therapy for chloroma (granulocytic sarcoma). (2011) (89)
Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. (2011) (86)
High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging (2010) (84)
Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. (1991) (81)
Low-grade MALT lymphoma of the stomach: a review of treatment options. (2000) (81)
Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. (2019) (77)
Diffuse Large B-Cell Lymphoma Version 1.2016. (2016) (76)
The influence of older age on breast cancer treatment decisions and outcome. (1996) (75)
Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. (1998) (75)
Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. (2018) (73)
Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. (1997) (72)
Non-Hodgkin's lymphomas, version 1.2013. (2013) (71)
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma (1999) (71)
Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkin's disease * (2004) (70)
ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic (2020) (70)
Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. (1984) (70)
Chemoradiotherapy for primary CNS lymphoma (2005) (69)
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (68)
Multiple myeloma, version 1.2013. (2013) (68)
Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines (2018) (67)
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. (2016) (67)
Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high‐dose methotrexate‐based chemotherapy (2008) (63)
Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) (2005) (63)
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. (2016) (61)
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. (2008) (59)
Multiple myeloma. Clinical practice guidelines in oncology. (2007) (59)
Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long‐term survivors of Hodgkin's disease: July 9–16, 2003, Bellagio, Italy (2005) (58)
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. (2018) (57)
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. (2015) (56)
Radiation treatment planning techniques for lymphoma of the stomach. (2005) (55)
The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. (2003) (55)
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. (2018) (54)
Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. (2015) (54)
Basic fibroblast growth factor confers growth inhibition and mitogen-activated protein kinase activation in human breast cancer cells. (1997) (52)
Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. (1977) (51)
R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy (2005) (49)
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma (2017) (49)
Clinical spectrum of pericardial effusion as the presenting feature of hypothyroidism. (1983) (48)
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma (2009) (47)
NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines (2017) (47)
Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer (1990) (47)
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making (2020) (47)
Non-Hodgkin's lymphomas, version 2.2014. (2014) (46)
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. (2015) (46)
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. (2006) (46)
Sarcoidosis following chemotherapy for Hodgkin's disease. (1994) (45)
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021) (45)
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. (2020) (44)
Hodgkin lymphoma, version 2.2015. (2015) (44)
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. (2013) (44)
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. (2020) (44)
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. (2008) (43)
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. (2012) (43)
Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population (2016) (42)
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. (2002) (42)
Alternatives in the Management of Gastric Lymphoma. (1991) (42)
Whole-brain radiotherapy in primary CNS lymphoma. (2011) (40)
Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells (1999) (40)
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). (2005) (39)
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. (2018) (37)
Disparities in survival by insurance status in patients with Hodgkin lymphoma (2015) (37)
Radiation‐Induced Salivary Gland Tumors: A Report of 18 Cases and a Review of the Literature (2003) (37)
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes (2016) (37)
Limited resection for breast cancer: a study of inked specimen margins before radiotherapy. (1987) (37)
Challenges and opportunities in primary CNS lymphoma: A systematic review. (2017) (37)
[¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. (2011) (36)
The patients perception of her breast following radiation and limited surgery. (1989) (35)
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation (2019) (35)
MALT Lymphomas: A radiation oncology viewpoint (2001) (34)
Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. (2010) (34)
Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. (1989) (34)
Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. (1992) (34)
Non‐Hodgkin's lymphoma associated with pregnancy a report of six cases, with a review of the literature (1985) (33)
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. (2006) (33)
Clinical Features and Outcome of Primary Pancreatic Lymphoma (2015) (32)
Primary CNS lymphoma: managing patients with spontaneous and AIDS-related disease. (1987) (32)
Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix. (1987) (31)
Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy (2020) (31)
Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival. (2015) (30)
Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease (1983) (30)
Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. (2006) (30)
Breast cancer after Hodgkin disease: hope for a safer cure. (2003) (29)
Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data. (2008) (29)
Advances in biology, diagnostics, and treatment of Hodgkin's disease. (2006) (29)
Four cycles of chemotherapy and regional radiation therapy for clinical early‐stage and intermediate‐stage Hodgkin's disease (1992) (29)
Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. (2018) (29)
Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines (2012) (29)
Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies (2018) (29)
Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone (2014) (28)
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. (1996) (27)
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. (2020) (27)
Pathways that Regulate Autophagy and their Role in Mediating Tumor Response to Treatment (2006) (27)
Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. (2006) (27)
Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. (2016) (26)
Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) (2017) (26)
Recurrent Neurotropic Chloroma: Report of a Case and Review of the Literature (2010) (26)
Long-term cardiac and pulmonary complications of cancer therapy. (2008) (26)
Long-term cardiac and pulmonary complications of cancer therapy. (2011) (25)
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. (2017) (25)
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation (2015) (25)
Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis. (2015) (25)
The role of radiation therapy in the management of primary central nervous system lymphoma (2015) (25)
Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group. (2018) (24)
Modern Radiotherapy for Extranodal Nasal-type NK/T-cell Lymphoma: Risk-adapted Therapy, Target Volume and Dose Guidelines from the International Lymphoma Radiation Oncology Group. (2021) (24)
Very low utility of surveillance imaging in early‐stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy (2015) (23)
The concept and evolution of involved site radiation therapy for lymphoma (2015) (23)
The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). (2019) (23)
FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. (2013) (23)
Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. (1991) (22)
Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. (2018) (22)
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations (2016) (21)
Radiotherapy of Follicular Lymphoma: Updated Role and New Rules (2014) (21)
Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease. (1995) (21)
Radiation-induced micronuclei formation in human breast cancer cells: dependence on serum and cell cycle distribution. (1997) (21)
Role of Radiation Therapy in Hodgkin’s Lymphoma (2009) (20)
Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review. (2009) (20)
Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant. (2018) (20)
Autologous bone marrow transplantation. (1991) (19)
The case for adjuvant radiation therapy in advanced Hodgkin's disease. (1996) (18)
Non-Hodgkin's Lymphomas, version 3.2012. (2012) (18)
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma (2021) (18)
Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B Cell Lymphoma in The Rituximab-Era. (2020) (18)
MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY (2019) (18)
Platelet-tumor cell interaction with the subendothelial extracellular matrix: relationship to cancer metastasis. (1985) (17)
Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. (2016) (17)
Radiation therapy in the treatment of lymphoma. (1999) (17)
Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor (2001) (17)
Changing role and decreasing size: Current trends in radiotherapy for hodgkin’s disease (2002) (17)
Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. (2017) (17)
Overexpression of basic fibroblast growth factor in MCF‐7 human breast cancer cells: Lack of correlation between inhibition of cell growth and MAP kinase activation (1998) (16)
A prospective study of ¹⁸FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies. (2014) (16)
Hodgkin disease/lymphoma. (2008) (16)
Radiation therapy for leukemia cutis. (2011) (15)
Lactation following conservation surgery and radiotherapy for breast cancer (1991) (15)
Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. (2019) (15)
Basic fibroblast growth factor potentiates cisplatinum-induced cytotoxicity in MCF-7 human breast cancer cells (1999) (15)
Hodgkin lymphoma. (2021) (14)
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. (2004) (14)
NCCN preliminary non-Hodgkin's lymphoma practice guidelines. (1997) (14)
Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. (2010) (14)
Diffuse large cell lymphoma. Prognostic factors with treatment. (1991) (14)
Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients. (2021) (13)
Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). (2018) (13)
Diagnostic and Therapeutic Considerations for Extramedullary Leukemia (2020) (13)
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. (2022) (12)
Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement. (2017) (12)
Sarcoid in cancer patients: clinical characteristics and associated disease status. (2015) (12)
Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy (2013) (12)
Eukaryotic Initiation Factor 2α - a Downstream Effector of Mammalian Target of Rapamycin - Modulates DNA Repair and Cancer Response to Treatment (2013) (12)
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population (2020) (11)
Favorable early-stage Hodgkin lymphoma. (2006) (11)
Secondary leukemia following treatment of Hodgkin's disease: ultrastructural and cytogenetic data in two cases with a review of the literature. (1983) (11)
Cutaneous Rosai-Dorfman disease of the right ear responsive to radiotherapy. (2012) (10)
The use of lymphoscintigraphy in treatment planning of primary breast cancer. (1989) (10)
Differentiating human leukemia cells express heparanase that degrades heparan sulfate in subendothelial extracellular matrix. (1988) (10)
A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation (2016) (10)
Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. (2005) (10)
TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin. (2015) (10)
Duct carcinoma-in-situ of the breast: Does conservation surgery and radiotherapy provide acceptable local control? (1990) (10)
Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma (2014) (10)
OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F‐FDG PET‐CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG (2017) (10)
Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting Presentation (2011) (10)
Factors affecting the outcome of autologous bone marrow transplantation. (1991) (9)
Evidence-based breast cancer screening guidelines for women who received chest irradiation at a young age. (2013) (9)
PET-Computed Tomography for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. (2011) (9)
Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice on outcome (2013) (9)
Treatment Options for Hodgkin's Disease During Pregnancy. (1990) (9)
Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy (2017) (9)
Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival (2016) (9)
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma (2019) (9)
Modified SMILE (mSMILE) is Active in the Treatment of Extranodal Natural Killer/T-Cell Lymphoma: A Single Center US Experience (2014) (9)
Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report (2017) (8)
Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat (2007) (8)
Primary cns lymphoma: Long-term results of an intensive combined modality therapy (1994) (8)
43. H. Pylori-Independent Malt Lymphoma of the Stomach: 10-Year Experience with 51 Patients Treated with Radiation Alone (2003) (8)
Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy (2014) (8)
Imaging of late complications from mantle field radiation in lymphoma patients. (2008) (8)
Effective treatment of malt lymphoma of the stomach with radiation alone (1998) (7)
Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment. (2006) (7)
Radiation therapy for stage III follicular lymphoma-often ignored, but still effective. (2001) (7)
Does radiotherapy still have a place in Hodgkin lymphoma? (2009) (7)
Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study (2021) (7)
BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE (2017) (7)
Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. (2018) (7)
Immunosuppression prior to marrow transplantation for sensitized aplastic anemia patients: comparison of TLI with TBI. (1988) (7)
Patients with H pylori-independent MALT lymphoma are curable with radiotherapy. (2011) (7)
SU‐FF‐J‐83: Inaccuracy of Fixed Threshold Segmentation for PET (2006) (7)
Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy? (2018) (7)
Radiotherapy for lung cancer: can IMRT decrease the risk of esophagitis (2001) (6)
Results of autologous bone marrow transplantation for acute leukaemia. (1989) (6)
Retinopathy in survivors of primary central nervous system lymphoma (2006) (6)
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? (2021) (6)
The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again (2011) (6)
Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease. (2020) (6)
Radiotherapy for Hodgkin lymphoma (2011) (5)
Early-Stage Hodgkin Disease: The Utilization of Radiation Therapy and Its Impact on Overall Survival (2014) (5)
Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience (2011) (5)
Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. (2020) (5)
Primary Mediastinal Large B Cell Lymphoma: Elucidating Optimal Therapy and Prognostic Factors; an Analysis in 141 Consecutive Patients Treated at Memorial Sloan Kettering from 1980–1999. (2004) (5)
Cancer Survivorship. Preface. (2008) (5)
150 : Reduced-Dose Whole Brain Radiotherapy (WBRT) Following Complete Response to Immuno-Chemotherapy in Patients With Primary CNS Lymphoma (PCNSL) (2006) (5)
Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma (2016) (5)
Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy (2018) (5)
Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2020) (5)
A Prospective Study of 18FDG-PET with CT scan Co-registration for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies (2010) (5)
A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA (2017) (5)
Abstract of ASTRO proffered papers, posters, and scientific exhibit to be presentedLong-term sequelae of total body irradiation, high dose chemotherapy, and autologous bone marrow transplantation for non-Hodgiqn's lymphoma (1994) (4)
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. (2020) (4)
Successful management of gastric perforation in stage IV diffuse large B-cell lymphoma with chemoradiation therapy, percutaneous endoscopy gastrostomy for gastric drainage, and percutaneous endoscopy jejunostomy for nutrition. (2013) (4)
Recommendations for the clinical management of the elderly patient with malignant lymphoma. (2018) (4)
NCCN practice guidelines for multiple myeloma (1998) (4)
Cancer survivorship: facing forward. (2008) (4)
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma. (2010) (4)
The effect of ABVD chemotherapy with and without mediastinal irradiation on pulmonary function and symptomsin early-stage Hodgkin's disease (1994) (4)
Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047 (2008) (4)
Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG) (2013) (3)
Re-visiting the role of radiation therapy in Hodgkin's disease. (1995) (3)
Cost-effectiveness analysis of first-line treatments for early-stage, low-grade follicular lymphoma. (2017) (3)
JNCCN NCCN Task Force Report : PET / CT Scanning in Cancer (2007) (3)
Chapter 18 – Total Body Irradiation (2012) (3)
A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma (2017) (3)
Favorable Outcome in Stage I-II Mantle Cell Lymphoma: A Report of 160 Patients From the International Lymphoma Radiation Oncology Group (ILROG) (2014) (3)
Patients with Relapsed/Refractory Large Cell Lymphoma Who Were Also Refractory to Salvage Chemotherapy: Outcome with Salvage Radiation Therapy Followed by Autologous Stem Cell Transplant (2018) (3)
by Human Platelet Heparitinase (1984) (3)
Outcomes of 210 Patients with Follicular and Marginal Zone Lymphomas Treated with 4 Gy of Radiation Therapy (2019) (3)
Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL). (2020) (3)
The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT (2021) (3)
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma (2019) (3)
Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL). (2004) (3)
SP-0496: Indications to radiotherapy for lymphoma in 2016: what is standard of care and what remains controversial? (2016) (3)
Hepatocellular carcinoma in Israel: relationship to hepatitis B virus infection. (1985) (3)
Modern radiation therapy for nodal non-Hodgkin lymphom-target definition and dose guidelines from the international lymphoma radiation oncology group (2017) (3)
Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. (2020) (2)
Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
Non-Hodgkin’s Lymphomas, Version 4.2014: Clinical Practice Guidelines in Oncology (2014) (2)
Principles of Radiation Techniques in Hodgkin Lymphoma (2011) (2)
Clinical Outcomes and Patterns of Relapse in 300 Patients With Early and Advanced-Stage Marginal Zone Lymphoma (2013) (2)
Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma (2008) (2)
Salvage Therapy for Relapsed and Refractory Hodgkin Lymphoma (2011) (2)
Hodgkin's disease—Part I: Epidemiology, pathology, staging and management of early stage disease (1996) (2)
Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy (2020) (2)
Optimal matchline blocking and matchline dosimetry for lymphoma patients. (2000) (2)
Local control and the sequencing of adjuvant systemic therapy with primary radiation for patients with early breast cancer (1992) (2)
HIGHLY FAVORABLE OUTCOMES WITH RT FOLLOWED BY ASCT IN LOW/LOW‐INTERMEDIATE SECONDARY AGE ADJUSTED IPI REL/REF DLBCL PATIENTS REFRACTORY TO SALVAGE CHEMOTHERAPY (2019) (2)
Chapter 12 – Principles, Indications, and Techniques of Radiation Therapy of Lymphomas (2006) (2)
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hodgkin Lymphoma, Version 2.2020 (2020) (2)
Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) (2017) (2)
Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. (2012) (2)
A Century of Total Body Irradiation (TBI) (2009) (2)
Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Amongst Radiation Oncology Residents (2019) (2)
Effects of hormonal deprivation or stimulation on the radiosensitivity of human breast cancer cells (1991) (2)
OUTCOMES OF 180 PATIENTS WITH INDOLENT LYMPHOMAS TREATED WITH VERY LOW DOSE (4 GY) RADIATION THERAPY ALONE (2019) (2)
Chapter 75 – Hodgkin Lymphoma: Clinical Manifestations, Staging, and Therapy (2018) (2)
Contrast media use in radiation oncology: a prospective, controlled educational intervention study with retrospective analysis of patient outcomes. (2010) (2)
Excretion of Ascaris lumbricoides during total body irradiation. (1994) (2)
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma (2022) (1)
Breast cancer in patients irradiated for hodgkin's disease: A clinical and pathological analysis of 44 events in 37 women (1991) (1)
Medical Diary for the ensuing Week (1881) (1)
Traditional and Modern Techniques for Radiation Treatment Planning (2011) (1)
DOSE AND/OR VOLUME REDUCTION USING CONSOLIDATION VOLUME RADIATION THERAPY (CVRT) LOWERS DOSE TO HEART AND LUNGS IN EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE (2017) (1)
Autologous Hematopoietic Cell Transplant Outcomes after Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2021) (1)
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations (2016) (1)
Excellent local control with involved-field radiotherapy following CHOP chemotherapy: analysis of 145 patients with early-stage intermediate-grade non-Hodgkin’s lymphoma (2001) (1)
Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Salvage Chemotherapy (2019) (1)
The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL). (2005) (1)
TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA TREATED WITH MODIFIED (m)SMILE AND INTENSITY‐MODULATED RADIOTHERAPY (IMRT), A SINGLE CENTER EXPERIENCE (2019) (1)
Innovative Approaches to Radiation Treatment for Mycosis Fungoides in the Setting of Collagen Vascular Disease (2015) (1)
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (2019) (1)
2584 : Health-Related Quality of Life in Long-Term Survivors of Autologous Hematopoietic-Cell Transplantation for Refractory and Relapsed Hodgkin’s Lymphoma (2006) (1)
Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy (2018) (1)
18FDG-PET With CT Scan Co-Registration for Radiation Treatment Planning of Lymphoma Patients (2007) (1)
Updates to the NCCN Guidelines (2013) (1)
Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL). (2016) (1)
In Reply to Scarpelli et al. (2020) (1)
In Reply to Zhang. (2017) (1)
Characteristics and Outcomes of Patients With Lymphocyte-Predominant Hodgkin Lymphoma Versus Classical Hodgkin Lymphoma: A Population-Based Analysis (2014) (1)
Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma? (2009) (1)
A Non-Stanford Mature Experience With Stanford V ± RT Regimen for Locally Extensive and Advanced Hodgkin's Lymphoma (HL) (2007) (1)
Brentuximab Vedotin and AVD Chemotherapy Followed by ISRT: A Safe Primary Treatment Regimen for Early-Stage, Unfavorable Hodgkin Lymphoma (2016) (1)
Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas (2020) (1)
Radiotherapy for Non-Hodgkin Lymphomas (2020) (1)
Excellent long-term experience with primary bone lymphoma: Analysis of prognostic factors. (2004) (1)
Comment on: "clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study)". (2014) (1)
Prognostic model for primary CNS lymphoma (PCNSL): Recursive partitioning analysis (RPA) of the MSKCC PCNSL population. (2006) (1)
ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. (2020) (1)
Involved-Site Radiation Therapy for H. Pylori-Independent Gastric MALT Lymphoma: 26 Years of Experience with 178 Patients (2018) (0)
Local Therapy in the Definitive Management of Castleman Disease (2018) (0)
Total lymphoid irradiation and high-dose chemotherapy followed by autologous bone marrow transplantation for relapsed or refractory Hodgkin's disease: 7-year experience (1992) (0)
Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study (2022) (0)
Influence of Post-second-line Chemotherapy PET Imaging and Involved Field Radiotherapy Prior to High Dose Therapy on Outcomes of Relapsed or Refractory Diffuse Large B Cell Lymphoma (2008) (0)
Multiple myeloma (2001) (0)
Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL). (2004) (0)
MEASUREMENT OF VERY LOW CORROSION RATES IN CLOSED SYSTEMS. (1972) (0)
A picture is worth a thousand words: a history of diagnostic imaging for lymphoma. (2021) (0)
Combined modality therapy for advanced stage hodgkin's disease: patterns of relapse, prognostic factors and the role of radiation therapy (1990) (0)
Identification of Gene Expression Signatures to Predict the Response of Low-Grade Lymphomas to Very Low Dose Radiation Therapy (2014) (0)
Practice Patterns in Early Stage Hodgkin Lymphoma: Analysis of the National Cancer Database (2019) (0)
NIMG-98. IDENTIFYING PATTERNS OF FAILURE AFTER INITIAL THERAPY IN PRIMARY CNS LYMPHOMA IN A LARGE PATIENT COHORT (2022) (0)
Breast Cancer After Hodgkin Disease (2017) (0)
What is the role of whole brain radiation therapy (WBRT) and high-dose cytarabine (Ara-C) as consolidation treatment after initial chemotherapy for primary CNS lymphoma (PCNSL)? (2007) (0)
Treatment Modality Choices and Outcome in Langerhans Cell Histiocytosis: Radiation Therapy Versus Other Modalities (2018) (0)
The outcome of patients with non-chemosensitive relapsed and refractory DLBCL salvaged with radiation therapy followed by autologous stem cell transplant. (2018) (0)
Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice. (2020) (0)
Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy (2021) (0)
Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas (2021) (0)
High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma. (2005) (0)
Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center (2021) (0)
Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology (2016) (0)
Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma (2022) (0)
[Acute myeloid leukemia: a late complication of the treatment for Hodgkin's disease]. (1983) (0)
Primary cns lymphoma — Improved survival with an intensive combined modality treatment approach (1989) (0)
Bronchial-Associated Lymphoid Tissue (BALT) Lymphoma: Characteristics and Treatment Outcome of 19 Cases. (2004) (0)
Book Review Lymphoma of the Nervous System Edited by Tracy T. Batchelor. 207 pp., illustrated. Boston, Butterworth–Heinemann, 2004. $74.95. 0-7506-7406-7 (2004) (0)
GRADE 3A FOLLICULAR LYMPHOMA CAN BE EFFECTIVELY CONTROLLED WITH VERY LOW DOSE RADIATION THERAPY (2019) (0)
2219 Primary bone lymphoma — characteristics, prognostic factors and the effect of treatment modality (1999) (0)
Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000-2015). (2022) (0)
lymphoma cell transplantation for relapsed or primary refractory diffuse large B-cell Rituximab and ICE (RICE) as second-line therapy prior to autologous stem (2013) (0)
changes in management, volume definition, and normal tissue dosimetry for many patients. A prospective trial is now underway to further characterize the impact of PET/CT in treatment planning for lymphoma patients. (2007) (0)
Early breast cancer: significance and effectiveness of local control by conservative surgery and primary radiation therapy. (1988) (0)
"Big Boom" Radiation Treatment (RT) of 4 Gy Single Fraction: Is It an Acceptable Alternative to "Boom Boom" Radiation Treatment 2 Gyx2 Fractions for Non-Hodgkin Lymphomas (NHL)? (2021) (0)
2156 Pulmonary complications following high dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) for non-Hodgkin's lymphoma (NHL): Analysis of risk factors (1996) (0)
Investigation Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma : A Population-Based Analysis (2015) (0)
Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma (2022) (0)
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study) (2020) (0)
[Primary adenocarcinoma of the appendix]. (1975) (0)
High Local Control And Overall Survival With Radiotherapy For Anaplastic Large Cell Lymphoma (2020) (0)
Cancer Management Chapter 26: Hodgkin lymphoma (2010) (0)
The NCCN Non-Hodgkin ’ s Lymphomas Clinical Practice Guidelines in OncologyTM (2010) (0)
toxicities and long term survival after autologous hematopoietic stem cell transplantation for older patients with relapsed refractory hodgkin lymphoma (2019) (0)
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL) (2019) (0)
Proceeding of the 37th Annual ASTRO meeting ASTRO refresher course abstract403 Hodgkin's disease — part 2: Management of advanced disease, relapsed disease, and long-term complications of treatment (1995) (0)
Adjubant chop chemotherapy following radiotherapy in stage I low and intermediate grade non-hodgkin's lymphoma: Results of a prospective randomized study (1991) (0)
2222 Improving the accuracy of tumor volume localization by the use of CT-simulation in patients with Hodgkin's disease (1999) (0)
Long-term Outcome of High-dose Salvage Chemoradiation for Patients with Early Stage Hodgkin Lymphoma (HL) Who Failed Initial Treatment with Combined Modality Treatment (CMT) or Chemotherapy Alone (C) (2010) (0)
Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT? (2019) (0)
Response Rates of Nodal Versus Extranodal Follicular and Marginal Zone Lymphomas to Very Low Dose Radiation Therapy of Only 4 Gy (2018) (0)
Langerhans Cell Histiocytosis (LCH) in the Modern Era: Excellent Local Control With Radiation Therapy (RT). (2016) (0)
Primary Follicular Lymphoma of the Gastrointestinal Tract: Importance of Stage and Treatment Regimen (2011) (0)
CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA (2021) (0)
Radiation Therapy for Patients with Diffuse Large B Cell Richter's Syndrome of CLL (2021) (0)
Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes (2022) (0)
Lymphoma: advances in imaging and radiotherapy - introductory editorial. (2021) (0)
Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma (2022) (0)
166 oral GASTRIC MALT LYMPHOMA: LONG-TERM EXCELLENT OUTCOME OF 103 PATIENTS TREATED WITH RADIOTHERAPY ALONE (2011) (0)
Basic Fibroblast Growth Factor Confers Growth Inhibition and Mitogen-activated Protein Kinase Activation in Human Breast Cancer Cells 1 (2005) (0)
SP-0208: Radiotherapy of Hodgkin Lymphoma: Revolutionary Roots, Challenging Present, Bright Horizons (2018) (0)
FDG-PET scanning for detection, staging and treatment planning of extranodal marginal zone lymphomas (2004) (0)
Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy. (2007) (0)
Overexpression of basic fibroblast growth factor confers negative growth regulation and radiosensitization in human breast cancer cells (1994) (0)
Principles of Radiation Therapy for Hodgkin Lymphoma (2020) (0)
Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report (2021) (0)
Accelerated Total Lymphoid Irradiation (TLI) as an Integral Component of High-dose Therapy (HDT) Salvage Regimen for Patients with Refractory and Relapsed Hodgkin Lymphoma (HL): 20 Years of Experience with 186 Patients (2009) (0)
A Proof-of-Principle Study of Split-Course Bridging Radiotherapy Prior to Commercial CD19 CAR T-Cell Therapies for Patients With Relapsed or Refractory B-Cell Lymphomas. (2021) (0)
Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma (2022) (0)
2038 Autologous bone marrow transplantation following high-dose chemotherapy with or without accelerated hyperfractionated total lymphoid irradiation for patients with refractory or relapsed Hodgkin's disease (1995) (0)
Outcomes for Patients Who Fail High Dose Chemoradiotherapy and Autologous Stem Cell Rescue for Relapsed and Primary Refractory Hodgkin Lymphoma. (2007) (0)
Positron Emission Tomography/Computed Tomography in Radiotherapy Treatment Planning (2010) (0)
Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL) (2004) (0)
No need for routine radiologic surveillance in early stage Hodgkin lymphoma (HL) treated with combined ABVD and radiotherapy (2014) (0)
Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy (2019) (0)
Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019 (2022) (0)
CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA (2019) (0)
Primary Central Nervous System Lymphoma (2018) (0)
Predictors of Response to Very Low Dose Radiotherapy (4Gy) for Indolent B-Cell Lymphomas: Is 4Gy Also Suitable for Potentially Curable Patients? (2021) (0)
Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience (2021) (0)
How I treat How I treat extramedullary acute myeloid leukemia (2011) (0)
Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies (2022) (0)
Local Recurrence After Radiation Therapy for Langerhans Cell Histiocytosis: Risk Stratification by Site of Disease (2017) (0)
Long-term outcomes of survivors of autologous hematopoietic-cell transplantation for refractory and relapsed Hodgkin's Disease. (2006) (0)
Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience (2021) (0)
Primary Intraocular Lymphoma: Excellent Outcomes With Ocular Radiation Therapy Alone (2012) (0)
Identification of effective therapy in Langerhans cell histiocytosis in the adult population. (2017) (0)
Treatment of Primary Central Nervous System Lymphoma with Cranial Irradiation and Combined Modality Therapy (2012) (0)
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma (2022) (0)
Relapsed and Primary Refractory Diffuse Large Cell Lymphoma (DLCL) Salvaged With Involved Field Radiotherapy (IFRT) & High Dose Chemotherapy (HDCT) Followed by Autologous Stem Cell Transplantation (ASCT) (2007) (0)
"Big Boom" (4 Gy x 1) Radiation Treatment (RT) Versus "Big Boom" (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL) (2022) (0)
Efficacy and Toxicity of Alternative Radiation Treatment Schemes for Patients With Hematologic Malignancies: A Collaborative ILROG COVID Era Report (2021) (0)
Future Prospects for Radiotherapy for Hodgkin Lymphoma (2011) (0)
Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: The Impact of Radiation Therapy on Overall Survival (2015) (0)
Non-Hodgkin's LymphomasPractice Guidelines in Oncology TM (2010) (0)
INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS (2019) (0)
303C Hodgkin's disease part 1: Pathology, staging, and management of early stage disease (1995) (0)
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting (2023) (0)
Overall survival in patients with Hodgkin lymphoma: Disparities by insurance status. (2015) (0)
Non-Hodgkin’s Lymphomas (1999) (0)
Prediction of Response to Very Low Dose Radiotherapy (4 Gy) in Mature B-Cell Lymphomas Using Metabolic Tumor Volume. (2021) (0)
Radiotherapy is an Effective Definitive Treatment for Limited Stage Grade 3A Follicular Lymphoma (2019) (0)
Modern radiation therapy for hodgkin lymphom-target definition and dose guidelines from the international lymphoma radiation oncology group (2017) (0)
Predictors of initial treatment in older adults with follicular non-Hodgkin lymphoma (2007) (0)
SP-0022 State of the art for indolent lymphoma (2019) (0)
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 (2022) (0)
Primary Hepatic Lymphoma: Role of Low-Dose Radiotherapy at a Single Institution with Genetic Characterization and Paired Literature Review (2022) (0)
2527 : Quality of Radiotherapy Reporting in Randomized Controlled Trials (RCTs) of Hodgkin Disease (HD) and Non-Hodgkin Lymphoma (NHL) (2006) (0)
Radioactive tracers for inhibitor evaluation (1971) (0)
Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy (2022) (0)
Long‐term outcomes of patients with limited‐stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era (2022) (0)
9203 Accelerated total lymphoid irradiation (TLI)-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma (HL): 20 years outcome with multivariate analysis (2009) (0)
Salivary Gland Tumors as Secondary Neoplasms: A Report of 18 Cases and a Review of the Literature (2003) (0)
61 – Non-Hodgkin's Lymphomas (2010) (0)
Deauville Dubiosity. (2020) (0)
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma (2022) (0)
LANGERHANS CELL HISTIOCYTOSIS IN ADULTS IS ASSOCIATED WITH INCREASED HEMATOLOGIC AND SOLID MALIGNANCIES (2017) (0)
Contrast Media Use in Radiation Oncology: An Educational Intervention Study with Retrospective Analysis of Patient Outcomes (2010) (0)
Curative radiation for orbital MZL: how much? (2017) (0)
Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy. (2022) (0)
Vacuolar-proton-ATPase is involved in the response of cancer cells to ionizing radiation and is a new target for radiosensitization (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joachim Yahalom?

Joachim Yahalom is affiliated with the following schools:

Hebrew University of Jerusalem
Stanford University
Harvard University

Joachim Yahalom's Academic­Influence.com Rankings

Joachim Yahalom's Degrees

Why Is Joachim Yahalom Influential?

Joachim Yahalom's Published Works

Published Works

What Schools Are Affiliated With Joachim Yahalom?

Joachim Yahalom's AcademicInfluence.com Rankings